N/A
Completed N=140
An Observational Study of the Real Life Management of the Psoriasis Patients Treated With Enbrel According to the New Reimbursement Criteria
Plaque Psoriasis Patients
Source: ClinicalTrials.gov NCT01557283 ↗
Enrolled (actual)
140
Serious AEs
5.1%
Results posted
Jun 2014
Primary outcomePrimary: Number of Weeks of Etanercept Treatment — 48.1874 weeks
Summary
With the new reimbursement criteria, we want:
To describe the average treatment duration of patients with Enbrel expressed as a number of weeks/year.
To describe the number of patients who receive continuous treatment To describe the number of patients who receive intermittent treatment To describe the number of weeks off treatment
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Weeks of Etanercept Treatment |
48.1874 | — |
| SECONDARY Number of Weeks of Off-Treatment |
5.5348 | — |
| SECONDARY Psoriasis Area and Severity Index (PASI) Score |
10.913; 6.680; 6.395; 5.571; 5.504; 5.468 | — |
| SECONDARY Percentage of Body Surface Area (BSA) Affected by Psoriasis |
14.189; 8.016; 7.579; 5.361; 5.706; 10.221 | — |
| SECONDARY Number of Participants With Reasons for Treatmant Discontinuation |
19; 7; 1; 1; 1; 1 | — |
Eligibility Criteria
Inclusion Criteria
- Patient restarts or is starting treatment with Enbrel for his/her psoriasis in alignment with reimbursement criteria
- Patients ≥18 year
- Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
Exclusion Criteria
N/A
Data sourced from ClinicalTrials.gov (NCT01557283). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.